# Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

> **NCT04965714** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Resectable Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Pegargiminase
- **PROCEDURE:** Resection

## Key facts

- **NCT ID:** NCT04965714
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-04-13
- **Primary completion:** 2023-02-10
- **Final completion:** 2023-02-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 patient accrual
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04965714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04965714, "Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04965714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*